IBS C News and Research

RSS

New therapy under development for the treatment of irritable bowel syndrome

A new therapy under development for the treatment of irritable bowel syndrome with diarrhea predominance appears to provide significant improvements in measures of quality of life, according to a study presented at the 69th Annual Meeting of the American College of Gastroenterology.

1 Nov 2004

Many factors influence quality of life for patients with irritable bowel syndrome

The quality of life for patients with irritable bowel syndrome is as related to non-gastrointestinal (GI) symptoms, including tiring easily and feeling tense, as it is to GI symptoms associated with the disorder

12 Sep 2004

New drug application for cilansetron, an investigational product for the treatment of irritable bowel syndrome

Solvay Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) for cilansetron, an investigational product being studied for the treatment of irritable bowel syndrome with diarrhea predominance (IBS-D), to the FDA on June 30, 2004.

1 Jul 2004

New risk factors associated with inflammatory bowel disease

Health researchers at the Christchurch School of Medicine and Health Sciences, Otago University, have found evidence of new risk factors associated with a debilitating illness called Inflammatory Bowel Disease (IBD).

24 Jun 2004

Mothers who are concerned about their own health may unwittingly be passing their anxieties on to their children

A new study of parenting suggests that mothers who suffer from certain illnesses like Irritable Bowel Syndrome are more likely to take their babies to the doctors for a range of minor problems.

24 May 2004

Significant symptom relief reported in clinical trial patients with irritable bowel syndrome

Solvay Pharmaceuticals unveiled this week results from a six-month study of both male and female patients and from a subgroup analysis of males with Irritable Bowel Syndrome with Diarrhea predominance (IBS-D).

24 May 2004

Researchers receive almost £1 million in funding for Irritable Bowel Syndrome

Researchers at The University of Nottingham, England have picked up almost £1 million in funding for a number of studies into a painful and distressing bowel condition that will affect up to one in 10 of the population at some time or another.

11 May 2004

FDA updates Zelnorm labeling a treatment of women with irritable bowel syndrome

The Food and Drug Administration (FDA) today announced the addition of new risk information to the health professional labeling for Zelnorm (tegaserod maleate). Zelnorm is a prescription medication for the short-term treatment of women with irritable bowel syndrome (IBS) whose primary bowel symptom is constipation.

30 Apr 2004